L’Italien, Gilbert
Popoff, Evan
Rogula, Basia
Powell, Lauren
Potashman, Michele
Dickson, Sam
O’Keefe, Patrick
Beiner, Melissa
Coric, Vlad
Perlman, Susan
Schmahmann, Jeremy D.
Hendrix, Suzanne
Funding for this research was provided by:
Biohaven Pharmaceuticals
Article History
Accepted: 22 April 2024
First Online: 7 May 2024
Declarations
:
: GLI, MP, MB, and VC are employees and shareholders at Biohaven Pharmaceuticals. EP, BR, and LP are employees at Broadstreet HEOR, which received consulting fees from Biohaven Pharmaceuticals. SH is the owner of Pentara Corp., which received consulting fees from Biohaven Pharmaceuticals. SD and PO are employees of Pentara Corp., which received consulting fees from Biohaven Pharmaceuticals. JS has served on the editorial board for The Cerebellum, Editorial Board, 1999. He is a principal investigator at Biohaven Pharmaceuticals. SP has nothing to disclose.
: Human Ethics and Consent to Participate declarations: not applicable.
: JDS declares no conflict of interests. He consults for Biohaven Pharmaceuticals and is site PI for Biohaven Pharmaceuticals clinical trials NCT03701399, NCT02960893 and NCT03952806; receives royalties from Oxford University Press, Elsevier, MacKeith Press, and Springer; and is the inventor of the Brief Ataxia Rating Scale, Cerebellar Cognitive Affective / Schmahmann Syndrome Scale, the Patient Reported Outcome Measure of Ataxia, and the Cerebellar Neuropsychiatry Rating Scale which are licensed to the General Hospital Corporation.